Pipeline: An adjuvant Therapy againt Anti Microbial Resistance with a Patented Small Molecule (BLT-001)

BioLink Therapeutics' adjuvant molecule is designed to work synergistically with existing antibiotics by targeting the mechanisms that confer resistance in Bacillus subtilis. Instead of directly killing the bacteria, the adjuvant molecule disrupts the bacterial defense systems—such as efflux pumps, biofilm formation, or enzyme-mediated antibiotic degradation—that typically neutralize antibiotic action. By inhibiting these resistance pathways, the adjuvant restores and amplifies the potency of standard antibiotics, allowing them to effectively eradicate the infection at lower doses and with reduced toxicity.

This strategy not only revives the clinical usefulness of older antibiotics but also helps slow the emergence of resistance by reducing selective pressure on bacteria. In settings like India, where overuse and misuse of antibiotics are widespread, BioLink’s adjuvant approach offers a transformative and cost-effective solution—empowering healthcare providers with a new weapon to combat resistant B.subtilis infections without needing to develop entirely new antibiotic classes. BioLink's new molecule is ready for filing patent in India. Clinical trial will be initiated following completion of preclinical development and regulatory approval.